Digital Health

Sonic Healthcare appointed new boss Jim Newcombe, who has launched a review of the company's underperforming US operations.

Leadership read: A change at the top rarely stays at the top. Sonic Healthcare's move reshapes the layer beneath it in Digital Health as a new leader sets priorities and the team re-forms. Watch the first two or three appointments that follow; they signal direction more reliably than any statement.

curated · 2026-08-20 · context →

Neko Health, a direct-to-consumer longevity body scanner company, is launching its first US clinic in New York City on September 24, 2026, with plans to expand to Miami, Washington DC, and San Francisco by end of 2026. The company has already established operations in Sweden and the UK.

Leadership read: Neko Health's expansion resets where the leadership need sits in Digital Health. Standing up a new market rewards operators with local networks and a record of building from scratch. The 12-to-18-month read across Americas favours country and commercial leadership hired close to the ground.

curated · 2026-08-18 · context →

Megan D. Bailey resigned as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026. Brian J. Caveney, M.D., expanded his leadership role over Biopharma Laboratory Services and related businesses.

Leadership read: A change at the top rarely stays at the top. Labcorp's move reshapes the layer beneath it in Digital Health as a new leader sets priorities and the team re-forms. Watch the first two or three appointments that follow; they signal direction more reliably than any statement.

curated · 2026-08-17 · context →

Australian health informatics company Alcidion expanding into Malaysia, showcasing patient flow and clinical decision-making platform to Malaysian healthcare providers.

Leadership read: Alcidion's expansion resets where the leadership need sits in Digital Health. Standing up a new market rewards operators with local networks and a record of building from scratch. The 12-to-18-month read across Asia favours country and commercial leadership hired close to the ground.

curated · 2026-08-17 · context →

Russia-linked ransomware group Cl0p claimed a mass cyberattack targeting Philips, Shell, and approximately 50 other companies

Leadership read: A breach is a governance event before it is a technical one. For Philips in Digital Health, the hiring consequence is rarely more engineers; it is senior accountability, security, risk and data governance reporting high enough to change decisions. Across EMEA, watch whether the response is a hire or a contractor; that distinction says how the board has read it.

curated · 2026-08-14 · context →

Doximity is expanding AI investment with 165 signed health system AI clients, signaling active product development and market adoption of AI capabilities in healthcare.

Leadership read: Doximity's launch shifts talent demand before revenue catches up. In Digital Health, taking a release to scale rewards product leaders with a commercial edge and operators who build the post-launch motion. Watch whether Doximity backs it with senior go-to-market hires across Americas — that separates a platform move from a one-off.

curated · 2026-08-07 · context →

Acentra Health acquired FEI Systems to expand its technology and clinical capabilities across Medicaid, long-term services and supports (LTSS), home- and community-based services (HCBS), and behavioral health verticals.

Leadership read: Consolidation shifts the leadership question from growth to integration. For Acentra Health in Digital Health, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Americas, watch whether the integration is properly resourced; deals are won or lost the year after they close.

curated · 2026-08-05 · context →

Hims & Hers launched Biotin + Minoxidil Gummy (June 2025), its first prescription gummy product, targeting wellness-focused consumers with CPG-style packaging and form factors. The product is reporting high adherence rates.

Leadership read: Hims & Hers's launch shifts talent demand before revenue catches up. In Digital Health, taking a release to scale rewards product leaders with a commercial edge and operators who build the post-launch motion. Watch whether Hims & Hers backs it with senior go-to-market hires across Americas — that separates a platform move from a one-off.

curated · 2026-08-05 · context →

PulsePoint launched Hatch, an agentic AI platform purpose-built for healthcare marketing with conversational capabilities integrated into proprietary health data foundation

Leadership read: PulsePoint's launch shifts talent demand before revenue catches up. In Digital Health, taking a release to scale rewards product leaders with a commercial edge and operators who build the post-launch motion. Watch whether PulsePoint backs it with senior go-to-market hires across Americas — that separates a platform move from a one-off.

curated · 2026-08-04 · context →

Labcorp launched the first FDA-approved IHC assay (PTEN companion diagnostic) for prostate cancer, enabling patient identification for combination treatment with capivasertib (TRUQAP®)

Leadership read: The operational weight here sits behind the word "first." Labcorp has moved from offering a laboratory-developed or research-use assay into a position as the sole provider of an FDA-approved companion diagnostic for a specific prostate cancer therapy, a regulatory designation that creates a durable clinical and commercial moat. Companion diagnostic approval ties patient access to a drug directly to a specific test, which means Labcorp is now embedded in the prescribing pathway for capivasertib. That is a qualitatively different commercial position than general oncology testing: the company now has a contractual and regulatory relationship with AstraZeneca's treatment protocol that generates recurring, protocol-mandated volume rather than discretionary referral volume. The related signals provided are thin on diagnostics or life-sciences comparables, the 12 product-launch signals in this window span fintech, defense, quantum computing, and consumer goods, with no direct oncology or IVD peers present. That absence is itself informative: FDA companion diagnostic approvals clear a regulatory bar that most product launches in adjacent sectors never approach, and the cadence in this specific corridor is low enough that each approval is a discrete market event rather than a pattern. Across companies operating at this intersection of regulated diagnostics and oncology therapeutics, the functional demand that consistently follows companion diagnostic clearance concentrates in regulatory affairs leadership with IVD expertise, commercial operations capable of managing pharma co-promotion structures, and medical affairs functions that can translate pathway-specific evidence into clinical adoption at the oncologist level.

curated · 2026-08-04 · context →

Signant Health launched Forecasting & Planning Assist™, an agentic AI capability designed for clinical supply chain forecasting and planning, leveraging latest AI advances.

Leadership read: Signant Health has committed to a specific operational claim: that agentic AI can be embedded directly into GxP-sensitive clinical supply workflows, forecasting and planning processes that govern drug availability in live trials, rather than sitting as an advisory layer alongside them. That distinction carries real weight. Clinical supply forecasting operates under regulatory documentation requirements and audit trail obligations that standard enterprise AI tooling was not built to satisfy. Shipping this as a named product capability, rather than an internal pilot, signals that Signant has made defensible decisions about data provenance, validation, and human-oversight architecture, decisions that are hard to reverse and that differentiate the product competitively if they hold up under sponsor scrutiny. The related signals set here is thin for this specific corridor. Of the twelve product_launch signals tracked in the same 90-day window, none fall within clinical operations or life-sciences supply chain AI; the comparables span fintech, defense, quantum hardware, and consumer goods. That absence is itself informative: agentic AI entering regulated clinical operations is still early and not yet showing cluster-level activity. This is a leading-edge, not a crowded, deployment. Companies at this stage of AI productization in regulated clinical and life-sciences infrastructure face concentrated demand in three functional areas: product leadership with validated-systems and regulatory-operations fluency, technical program management at the sponsor-facing integration layer, and commercial leadership capable of translating probabilistic AI outputs into the risk-tolerance language of clinical procurement and compliance teams.

curated · 2026-08-03 · context →

Hippocratic AI acquired Grove AI, a startup formed in 2024 that uses voice agents to recruit eligible patients for clinical trials. The acquisition occurred in 2026, approximately 2 years after Grove AI's founding.

Leadership read: Hippocratic AI's acquisition of Grove AI is less a product purchase than a workflow commitment. Before this deal, Hippocratic operated voice agents in patient-facing care navigation; Grove AI had built a distinct vertical, automated voice-led recruitment into clinical trials, with its own eligibility-screening logic and sponsor relationships. Absorbing that capability means Hippocratic now carries obligations to the clinical-trial recruitment pipeline: sponsor contracts, IRB-adjacent compliance requirements, and patient-data handling norms that sit closer to research regulation than care delivery. That is a materially different operating surface than it held before. This is one of 12 M&A signals we have tracked across sectors in the last 90 days. Within that set, the healthcare-adjacent moves are the most instructive comparables: Wise Equity's acquisition of E-Pharma Trento with an explicit bolt-on mandate signals platform-building logic in pharma services; BioMarin-Amicus points to integration scale at the therapeutic level. The Hippocratic-Grove deal fits a narrower but accelerating pattern. AI-native platforms acquiring point-solution startups at the 18–24 month mark, before those startups have had to build their own enterprise sales motion, folding the capability into a broader distribution engine. Companies consolidating at this stage of AI-in-clinical-operations activity face rising functional pressure in regulatory and compliance leadership capable of spanning care delivery and research protocols, alongside commercial leadership that can sell into both health system and pharma-sponsor buyers, two procurement cultures with little overlap.

curated · 2026-07-31 · context →